Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD.
| Published in: | Gastroenterology & Hepatology Vol. 21; pp. 15 - 17 |
|---|---|
| Format: | tables/charts Journal Article |
| Published: |
Gastro-Hep Communications, Inc
2025 Supplement
|
| Online Access: | View this record in EBSCOhost |